GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Total Equity

Elanix Biotechnologies AG (FRA:ELN) Total Equity : €-1.40 Mil (As of Dec. 2018)


View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Total Equity?

Elanix Biotechnologies AG's total equity for the quarter that ended in Dec. 2018 was €-1.40 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Elanix Biotechnologies AG Total Equity Historical Data

The historical data trend for Elanix Biotechnologies AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Total Equity Chart

Elanix Biotechnologies AG Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 16.08 15.43 0.54 -1.40

Elanix Biotechnologies AG Semi-Annual Data
Dec08 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.43 18.10 0.54 15.25 -1.40

Elanix Biotechnologies AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Elanix Biotechnologies AG's Total Equity for the fiscal year that ended in Dec. 2018 is calculated as

Total Equity=Total Assets(Q: Dec. 2018 )-Total Liabilities(Q: Dec. 2018 )
=1.078-2.48
=-1.40

Elanix Biotechnologies AG's Total Equity for the quarter that ended in Dec. 2018 is calculated as

Total Equity=Total Assets(Q: Dec. 2018 )-Total Liabilities(Q: Dec. 2018 )
=1.078-2.48
=-1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elanix Biotechnologies AG Total Equity Related Terms

Thank you for viewing the detailed overview of Elanix Biotechnologies AG's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Total Equity
Comparable Companies
XSAT:ACUC XCNQ:VENI BOM:524202 CXUS ETST INNV BOM:524711 BOM:531726 CYIG ASX:AZT BOM:530233 SGX:BFK BUE:ROSE WAR:CBD XCNQ:RQB NSE:PAR BOM:540694 TSXV:GYSR OSTO:GABA XCNQ:GSTR
Traded in Other Exchanges
N/A
Address
Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474
Website
https://www.elanixbiotechnologies.ch
Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines